Basel, Switzerland

Carla Garofalo

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Tillotts Pharma Ag. Active years: 2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carla Garofalo. Retrieved from https://idiyas.com/inventor/carla-garofalo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Carla Garofalo

Introduction

Carla Garofalo is a prominent inventor based in Basel, Switzerland. She has made significant strides in the field of pharmaceuticals, particularly with her innovative work on microgel particles.

Latest Patents

Carla holds a patent for "Microgel particles containing nanotubes loaded with an active pharmaceutical ingredient." This invention relates to microgel particles that incorporate nanotubes, which are loaded with an active pharmaceutical ingredient. The patent also details a process for the preparation of these particles and a pharmaceutical composition that includes them.

Career Highlights

Carla is currently employed at Tillotts Pharma AG, where she continues to contribute to advancements in pharmaceutical technology. Her work focuses on developing innovative solutions that enhance drug delivery systems.

Collaborations

Some of Carla's notable coworkers include Jan Kendall De Kruif and Gisela Ledergerber, who collaborate with her on various projects within the pharmaceutical sector.

Conclusion

Carla Garofalo's contributions to the field of pharmaceuticals through her innovative patents and collaborative efforts highlight her role as a key figure in advancing medical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…